Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent for treating rhinorrhea in adults and children aged 6+; U.S. sales reached $63M in May 2025.

• Lupin, a global pharmaceutical leader, offers this solution in over 100 markets with diverse product portfolios.
• Indicated for allergic and nonallergic perennial rhinitis, providing symptomatic relief for nasal discharge.
• IQVIA data shows $63 million in annual U.S. sales in May 2025 for the RLD Atrovent equivalent formulation.